ENTRECTINIB for Non-small cell lung cancer: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 412 adverse event reports in the FDA FAERS database where ENTRECTINIB was used for Non-small cell lung cancer.
Most Reported Side Effects for ENTRECTINIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Dizziness | 143 | 9.6% | 13 | 25 |
| Off label use | 137 | 9.2% | 20 | 10 |
| Death | 126 | 8.5% | 125 | 6 |
| Disease progression | 105 | 7.0% | 38 | 15 |
| Taste disorder | 68 | 4.6% | 7 | 9 |
| No adverse event | 65 | 4.4% | 0 | 1 |
| Constipation | 60 | 4.0% | 3 | 9 |
| Fatigue | 60 | 4.0% | 6 | 11 |
| Drug ineffective | 58 | 3.9% | 13 | 4 |
| Blood creatinine increased | 57 | 3.8% | 7 | 17 |
| Nausea | 56 | 3.8% | 3 | 11 |
| Renal impairment | 53 | 3.6% | 5 | 8 |
| Diarrhoea | 52 | 3.5% | 7 | 15 |
| Weight increased | 51 | 3.4% | 3 | 9 |
| Cardiac failure | 45 | 3.0% | 11 | 24 |
Other Indications for ENTRECTINIB
Lung neoplasm malignant (339)
Product used for unknown indication (196)
Neoplasm (56)
Lung adenocarcinoma (54)
Neoplasm malignant (47)
Non-small cell lung cancer metastatic (41)
Metastases to central nervous system (25)
Bronchial carcinoma (23)
Pancreatic carcinoma metastatic (18)
Lung adenocarcinoma stage iv (16)
Other Drugs Used for Non-small cell lung cancer
NIVOLUMAB (9,987)
CARBOPLATIN (7,939)
PEMBROLIZUMAB (6,893)
OSIMERTINIB (6,358)
PEMETREXED (5,179)
PACLITAXEL (4,609)
ATEZOLIZUMAB (4,459)
BEVACIZUMAB (4,136)
DURVALUMAB (3,396)
ERLOTINIB (3,359)